31 October 2019
Visiongain has launched a new pharma report Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.
The global attention deficit hyperactivity disorder is anticipated to witness strong growth during the forecast period. Factors such as the growing prevalence of the ADHD cases in adults and children, growing awareness coupled with support from the government as well as rising regulatory approvals will drive market growth.
The lead analyst of the report commented "The global attention deficit disorder market is one that is driven by innovation. This is vital for maintaining the rich pipeline of ADHD drugs seen in the market today. There is increasing focus to identify and treat ADHD that currently are undertreated and try to serve these neglected markets. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market. This prevents stagnation within the market and will help drive the growth of attention deficit disorder market."
Leading companies featured in the report include Eli Lilly, Johnson and Johnson, Lupin Limited, Mallinckrodt & Co., Neos Therapeutics, Pfizer Inc., Purdue Pharma L.P., Takeda Pharmaceuticals and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.